$4.93 Billion is the total value of Artal Group S.A.'s 146 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $38,832,000 | – | 400,000 | +100.0% | 0.79% | – |
| OTLY | New | OATLY GROUP ABsponsored ads | $36,690,000 | – | 1,500,000 | +100.0% | 0.74% | – |
| TALS | New | TALARIS THERAPEUTICS INC | $30,324,000 | – | 2,064,262 | +100.0% | 0.62% | – |
| VERV | New | VERVE THERAPEUTICS INC | $30,125,000 | – | 500,000 | +100.0% | 0.61% | – |
| GRPH | New | GRAPHITE BIO INC | $21,511,000 | – | 700,000 | +100.0% | 0.44% | – |
| AMAM | New | AMBRX BIOPHARMA INCsponsored ads | $16,660,000 | – | 850,000 | +100.0% | 0.34% | – |
| DLO | New | DLOCAL LTD | $15,496,000 | – | 295,000 | +100.0% | 0.32% | – |
| LFST | New | LIFESTANCE HEALTH GROUP INC | $13,930,000 | – | 500,000 | +100.0% | 0.28% | – |
| AGL | New | AGILON HEALTH INC | $12,171,000 | – | 300,000 | +100.0% | 0.25% | – |
| LYEL | New | LYELL IMMUNOPHARMA INC | $11,368,000 | – | 700,000 | +100.0% | 0.23% | – |
| CYTK | New | CYTOKINETICS INC | $9,895,000 | – | 500,000 | +100.0% | 0.20% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $8,796,000 | – | 100,000 | +100.0% | 0.18% | – |
| RXRX | New | RECURSION PHARMACEUTICALS INcl a | $7,300,000 | – | 200,000 | +100.0% | 0.15% | – |
| BHG | New | BRIGHT HEALTH GROUP INC | $5,243,000 | – | 305,555 | +100.0% | 0.11% | – |
| DYNS | New | DYNAMICS SPECIAL PURPOSE COR | $4,970,000 | – | 500,000 | +100.0% | 0.10% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $4,893,000 | – | 431,894 | +100.0% | 0.10% | – |
| IMMP | New | IMMUTEP LTDsponsored ads | $3,870,000 | – | 1,000,000 | +100.0% | 0.08% | – |
| MOLN | New | MOLECULAR PARTNERS AGads | $2,049,000 | – | 100,000 | +100.0% | 0.04% | – |
| LU | New | LUFAX HOLDING LTD | $565,000 | – | 50,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-06-22 |
| 3 | 2023-06-15 |
| 4 | 2023-06-05 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.